[Possibilities and expectations of hybridoma technology: national and international response]

The application of monoclonal antibodies has become a great commercial success. It is interesting to know the factors that have contributed to this. A few years ago a case study was published--financed by the EEC--in which various factors were studied. This study is briefly discussed. The Dutch government has identified hybridoma technology as important for Dutch industry and is attempting to stimulate the research effort by making innovation funds in the area of biotechnology available. The various possibilities that have been created are discussed. Finally, attention is given to development in the area of computerized hybridoma data banks. Some conclusions and recommendations are given.